Economic assessment of the secondary prevention of ischaemic events with lysine acetylsalicylate

PharmacoEconomics

Volumn 18, Issue 2, 2000, Pages 185-200

  Marissal, J P ^a   Selke, B ^a   Lebrun, T ^a  

^a Centre de Recherches Economiques   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; LYSINE ACETYLSALICYLATE;

ADOLESCENT; ADULT; AGED; ANGINA PECTORIS; ARTICLE; CEREBROVASCULAR ACCIDENT; CHILD; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ECONOMIC EVALUATION; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROPHYLAXIS; SECONDARY PREVENTION; SOCIAL SECURITY; TREATMENT OUTCOME;

EID: 0033883464     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200018020-00008     Document Type: Article

References (72)

1. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial
2. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia
3. The economic impact of tacrine in the treatment of Alzheimer's disease
4. Treatment of Alzheimer disease with tacrine: A cost-analysis model
5. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada
6. An economic evaluation of donepezil in the treatment of Alzheimer's disease
7. Estimating long term cost savings from treatment of Alzheimer's disease: A modelling approach
8. The West Of Scotland Coronary Prevention Study: Economic benefit analysis of primary prevention with pravastatin in WOSCOPS
9. Cholesterol lowering and the use of healthcare resources: Results of the Scandinavian Simvastatin Survival Study
10. Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease
11. Costs and effects of long-term oral anticoagulant treatment after MI
12. Application of the findings of the European stroke prevention study 2 (ESPS-2) to a New Zealand ischaemic stroke cost analysis
13. Cost of stroke in the Netherlands from a societal perspective
14. Direct medical costs of coronary artery disease in the United States
15. An economic analysis of ischaemic heart disease in Switzerland
16. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, MI, and stroke by prolonged antiplatelet therapy in various categories of patients
17. Incidence and survival rates during a two-year period, of intracerebral and subaraclinoid haemorrhages, cortical infarcts, lacunes and transient ischaemic attacks: The stroke registry of Dijon
18. Management of stable angina pectoris
19. Risk of MI and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease
20. Aspirin (75 mg/day) after an episode of unstable coronary artery disease long-term effects on the risk for M.I., occurrence of severe angina and the need for revascularization
21. Prevention of serious cardiac events by low-dose aspirin in patients with silent MI
22. Double-blind trial of aspirin in primary prevention of MI in patients with stable chronic angina pectoris
23. Aspirin and secondary mortality after MI
24. Trial of acetylsalicylic acid in the secondary prevention of mortality from MI
25. Secondary prevention of MI: A comparison of acetylsalicylic acid, placebo and phenprocoumon
26. The German-Austrian aspirin trial: A comparison o f acetylsalicylic acid, placebo and phenprocoumon in the secondary prevention of MI
27. The coronary drug project: Design, methods and baseline results
28. Aspirin in coronary heart disease
29. Aspirin in coronary heart disease
30. Prevention of reinfarction with acetylsalicylic acid
31. AMIS: A randomized controlled trial of aspirin in persons recovered from MI
32. AMIS: The aspirin MI study: Final results
33. Controlled trial of aspirin in cerebral ischemia
34. Controlled trial of aspirin in cerebral ischemia Pt II: Surgical group
35. Controlled trial of aspirin in cerebral ischemia: An addendum
36. Danish very- low-dose aspirin after carotid endarterectomy trial
37. Aspirin in patients with cerebral ischemia and normal angiograms or non-surgical lesions
38. High-dose acetylsalicylic acid after cerebral infarction: A Swedish co-operative study
39. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events
40. Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischaemic attacks: A Danish cooperative study
41. AICLA controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia
42. Essai cooperatif controle de prevention secondaire des accidents ischemiques cerebraux lies a l'atherosclerose par l'aspirine et le dipyridamole
43. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Interim results
44. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Final results
45. Results of the CAPRIE trial: Efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events
46. The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in patients at risk of ischaemic events. International stroke trial. Chinese acute stroke trial
47. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin: The stroke prevention reversible ischemia trial (SPIRIT) study
48. Randomised double-blind trial of fixed low-dose warfarin with aspirin after MI: Coumadin Aspirin Reinfarction Study (CARS) investigators
49. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrilation: Stroke prevention in atrial fibrilation III randomised clinical trial
50. Low-intensity anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: A randomized trial in patients with mechanical prosthetic heart valves
51. The gastrointestinal toxicity of aspirin: An overview of randomised controlled trials
52. Le cout des maladies vasculaires cerebrales non hemorragiques
53. Devenir socio-professionnel des patients traites pour infarctus du myocarde
54. Incidence du niveau de revenu chez des patients atteints d'infarctus du myocarde et thrombolyses
55. Economic foundations of cost-effectiveness analysis
56. Is aspirin underused in myocardial infarction?
57. ASHP therapeutic position statement on the use of aspirin for prophylaxis of MI
58. Theoretical issues in cost-effectiveness analysis
59. Accounting for future costs in medical cost-effectiveness analysis
60. Preventing fatal diseases increases healthcare costs: Cause elimination life table approach
61. Too many proposals pass the benefit cost test
62. Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?
63. On the decision rules of cost-effectiveness analysis
64. Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems
65. Audit of secondary prophylaxis after MI
66. Process and outcome of care for acute MI among Medicare beneficiaries in Connecticut: A quality improvement demonstration project